Please login to the form below

Not currently logged in
Email:
Password:

Abeona Therapeutics appoints new additions to board of directors

Stefano Buono and Richard Van Duyne join the biopharma

AbeonaAbeona Therapeutics, a clinical stage biopharmaceutical company focused on developing cell and gene therapies, has expanded its board of directors through the appointment of Stefano Buono and Richard Van Duyne.

Buono was previously the chief executive officer and president of Advanced Accelerator Applications, an international radiopharmaceutical company he founded in 2002.

He said: “Abeona’s ambitious gene and cell therapies have the promise to bring treatments to patients for whom there are currently no treatment options available.

“Its mission to bring relief and an extended, better quality of life to patients, many of whom are children, is closely aligned with my own values, and I am happy to be able to contribute to the company.”

Van Duyne, on the other hand, has previously held executive-level business development positions, which led him to serve as global head of business development for Daiichi Sankyo.

He said: “I am excited to be joining Abeona’s board at such a time of momentum for the company and the gene therapy space as a whole.

“I believe Abeona’s pipeline has significant potential to bring transformative therapies to patients with devastating, life-threatening diseases.”

31st May 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics